Stifel Initiates Coverage On Definium Therapeutics with Buy Rating, Announces Price Target of $30

Benzinga Newsdesk www.benzinga.com Positive 53.9%

Neg 0% Neu 0% Pos 53.9%

Stifel analyst Paul Matteis initiates coverage on Definium Therapeutics (NASDAQ:DFTX) with a Buy rating and announces Price Target of $30.